Responses
Regular and Young Investigator Award Abstracts
Cell Therapies
315 Characterization of CT-0508, an anti-HER2 chimeric antigen receptor macrophage (CAR-M), manufactured from patients enrolled in the phase 1, first in human, clinical trial of CT-0508
Compose a Response to This Article
Other responses
No responses have been published for this article.